<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02139826</url>
  </required_header>
  <id_info>
    <org_study_id>IX-0102</org_study_id>
    <nct_id>NCT02139826</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability and Food Effect Study of IX-01 Capsules in Healthy Men</brief_title>
  <official_title>A Randomised, Single-dose, 3-way Crossover Study to Evaluate the Relative Bioavailability of the IX-01 Capsule Formulation Compared With the IX-01 Aqueous Dispersion Formulation, and the Effect of Food on the IX-01 Capsule Formulation, in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ixchelsis Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ixchelsis Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the absorption and blood levels of IX-01 when given&#xD;
      as a capsule compared to liquid form, and how food affects the absorption in healthy men.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Bioavailability (Frel) of a Capsule Compared to a Liquid Formulation of IX-01 While Fasting, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve From Time 0 to Infinity</measure>
    <time_frame>Pre-dose up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in the Fed State Compared to the Fasted State, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve From Time 0 to Infinity</measure>
    <time_frame>Pre-dose up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Bioavailability (Frel) of a Capsule Compared With a Liquid Formulation of IX-01 While Fasting, as Calculated by a Ratio of Peak Plasma Concentrations</measure>
    <time_frame>Pre-dose up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in a Fed State Compared to a Fasted State, as Calculated by a Ratio of Peak Plasma Concentrations</measure>
    <time_frame>Pre-dose up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time 0 to Infinity, Following a Single Dose of IX-01</measure>
    <time_frame>Pre-dose and up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of IX-01</measure>
    <time_frame>Pre-dose and up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Peak Plasma Concentration (Tmax) of IX-01</measure>
    <time_frame>Pre-dose up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half Life (t1/2) of IX-01</measure>
    <time_frame>Pre-dose up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Rate Constant (Kel) of IX-01</measure>
    <time_frame>Pre-dose up to 96 hours post last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Measurable Sample of IX-01</measure>
    <time_frame>Pre-dose to the time of the last measurable sample</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of IX-01 in Cerebrospinal Fluid (CSF) After a Single Dose of the Liquid Formulation of IX-01</measure>
    <time_frame>1, 2, 4 and 6 hours after dosing</time_frame>
    <description>Listed by time point of 1, 2, 4, 6 hours post dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs</measure>
    <time_frame>Baseline to study completion (approximately 6 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>IX-01 Capsule while Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IX-01 Aqueous Dispersion while Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IX-01 Capsule after Food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IX-01</intervention_name>
    <arm_group_label>IX-01 Aqueous Dispersion while Fasting</arm_group_label>
    <arm_group_label>IX-01 Capsule after Food</arm_group_label>
    <arm_group_label>IX-01 Capsule while Fasting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A body mass index (Quetelet index) in the range 18-30 kilograms/meters squared (kg/m2)&#xD;
&#xD;
          -  Body Mass Index = weight [kg] divided by (height [m])2&#xD;
&#xD;
          -  Total body weight greater than (&gt;)50 kg at screening&#xD;
&#xD;
          -  Ability to communicate satisfactorily with the investigator and to participate in, and&#xD;
             comply with the requirements of, the entire trial&#xD;
&#xD;
          -  Participants and their partners must be willing to use adequate forms of contraception&#xD;
             and to comply with the contraception requirements during the trial and for 4 months&#xD;
             after the last dose of medication&#xD;
&#xD;
          -  Willingness to give written consent to have data entered into The Over Volunteering&#xD;
             Prevention System&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant abnormal history, physical findings, ECG, or laboratory values at&#xD;
             the pre-trial screening assessment, including:&#xD;
&#xD;
               -  Lipid and/or liver function test results &gt;1.25 x Upper Limit of Normal (ULN) or&#xD;
                  other clinical laboratory blood biochemistry test results outside the normal&#xD;
                  reference range unless discussed and approved by sponsor&#xD;
&#xD;
               -  International normalised ratio (INR) of &gt;1.2 or a platelet count &lt; 150 x&#xD;
                  109/Liter&#xD;
&#xD;
               -  History of unexplained syncope&#xD;
&#xD;
               -  Family history of unexplained sudden death, or sudden death due to long QT&#xD;
                  syndrome&#xD;
&#xD;
               -  Fridericia Correction Formula (QTcF) interval &gt;450 milliseconds (msec) at&#xD;
                  screening&#xD;
&#xD;
               -  Bundle branch block and other conduction abnormalities, other than mild first&#xD;
                  degree atrio-ventricular block&#xD;
&#xD;
               -  Irregular rhythms other than sinus arrhythmia or occasional supraventricular&#xD;
                  ectopic beats&#xD;
&#xD;
               -  T-wave configuration of insufficient quality for determination of QT interval, as&#xD;
                  assessed by the investigator&#xD;
&#xD;
          -  Presence of acute or chronic illness or history of chronic illness sufficient to&#xD;
             invalidate participation in the trial&#xD;
&#xD;
          -  Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory,&#xD;
             haematological, renal or neurological function, diabetes mellitus, coronary heart&#xD;
             disease, or history of any psychotic mental illness&#xD;
&#xD;
          -  Surgery (for example (e.g.) stomach bypass) or medical condition that might affect&#xD;
             absorption, metabolism or elimination of medicines&#xD;
&#xD;
          -  Any skin condition, abnormality of the lumbar spine, medical or surgical condition&#xD;
             that would preclude lumbar puncture (e.g. coagulopathy, local or systemic infection,&#xD;
             left ventricular outflow obstruction, aortic stenosis, previous back surgery)&#xD;
&#xD;
          -  Presence or history of severe adverse reaction to any drug&#xD;
&#xD;
          -  Use of any prescription or over-the-counter medicine during the 14 days before the&#xD;
             first dose of trial medication, or intention to use any medicine during the trial,&#xD;
             with the exception of short courses of medication considered by the investigator not&#xD;
             to interfere with the safety of the participant or the integrity of the trial data&#xD;
             (such as acetaminophen (paracetamol))&#xD;
&#xD;
          -  Current use of any herbal remedy or nutritional supplement, or intention to use any&#xD;
             such product during the study&#xD;
&#xD;
          -  Participation in another clinical trial of a new chemical entity or a prescription&#xD;
             medicine within the previous 3 months.&#xD;
&#xD;
          -  Previous participation in this trial or any other clinical trial of an oxytocin&#xD;
             receptor antagonist&#xD;
&#xD;
          -  Presence or history of drug or alcohol abuse, or intake of more than 21 units of&#xD;
             alcohol weekly or more than 5 cigarettes daily&#xD;
&#xD;
          -  Blood pressure and heart rate in supine position at the screening examination outside&#xD;
             the ranges 100-130 millimeters of mercury (mm Hg) systolic, 60-90 mm Hg diastolic;&#xD;
             heart rate 50-100 beats/minute. Measurements must be made in duplicate, and all values&#xD;
             must fall within the acceptable ranges&#xD;
&#xD;
          -  Possibility that the participant will not cooperate with the requirements of the&#xD;
             protocol&#xD;
&#xD;
          -  Evidence of drug abuse on urine testing&#xD;
&#xD;
          -  Positive test for hepatitis B, hepatitis C, Human Immunodeficiency Virus 1 (HIV1) or&#xD;
             Human Immunodeficiency Virus 2 (HIV2)&#xD;
&#xD;
          -  Loss of more than 400 mL blood during the 3 months before the trial, e.g. as a blood&#xD;
             donor&#xD;
&#xD;
          -  Objection by General Practitioner (GP), on medical grounds, to participant entering&#xD;
             trial&#xD;
&#xD;
          -  Employee of the investigator site or any company involved in sponsoring, organizing or&#xD;
             conducting the trial, or immediate family of the employee&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email: Ixchelsis@Choruspharma.com</last_name>
    <role>Study Director</role>
    <affiliation>Ixchelsis Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 12, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <results_first_submitted>August 5, 2020</results_first_submitted>
  <results_first_submitted_qc>August 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2020</results_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One participant withdrew between arms following a non-serious adverse event - unlikely to be treatment-related</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>Single oral dose of 800 milligrams IX-01 as an aqueous dispersion while fasting, or as a capsule while fasting, or as capsule while fed, in each of 3 treatment periods&#xD;
IX-01</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>All 12 randomized participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relative Bioavailability (Frel) of a Capsule Compared to a Liquid Formulation of IX-01 While Fasting, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve From Time 0 to Infinity</title>
        <time_frame>Pre-dose up to 96 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IX-01 Capsule While Fasting</title>
            <description>Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Bioavailability (Frel) of a Capsule Compared to a Liquid Formulation of IX-01 While Fasting, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve From Time 0 to Infinity</title>
          <units>Ratio: capsule fasted/acqueous fasted</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.93" lower_limit="90.8" upper_limit="109.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in the Fed State Compared to the Fasted State, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve From Time 0 to Infinity</title>
        <time_frame>Pre-dose up to 96 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IX-01 Capsule After Food</title>
            <description>Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in the Fed State Compared to the Fasted State, as Calculated by a Ratio of Area Under the Plasma Concentration Time Curve From Time 0 to Infinity</title>
          <units>Ratio: capsule fed/fasted</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.85" lower_limit="135.25" upper_limit="163.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relative Bioavailability (Frel) of a Capsule Compared With a Liquid Formulation of IX-01 While Fasting, as Calculated by a Ratio of Peak Plasma Concentrations</title>
        <time_frame>Pre-dose up to 96 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IX-01 Capsule While Fasting</title>
            <description>Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Bioavailability (Frel) of a Capsule Compared With a Liquid Formulation of IX-01 While Fasting, as Calculated by a Ratio of Peak Plasma Concentrations</title>
          <units>Ratio: capsule/aqueous</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.78" lower_limit="96.76" upper_limit="158.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in a Fed State Compared to a Fasted State, as Calculated by a Ratio of Peak Plasma Concentrations</title>
        <time_frame>Pre-dose up to 96 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IX-01 Capsule After Food</title>
            <description>Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Bioavailability (Frel) of a Capsule Formulation of IX-01 in a Fed State Compared to a Fasted State, as Calculated by a Ratio of Peak Plasma Concentrations</title>
          <units>Ratio: capsule fed/fasting</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.46" lower_limit="137.15" upper_limit="224.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Time Curve From Time 0 to Infinity, Following a Single Dose of IX-01</title>
        <time_frame>Pre-dose and up to 96 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IX-01 Aqueous Dispersion While Fasting</title>
            <description>Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O2">
            <title>IX-01 Capsule While Fasting</title>
            <description>Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O3">
            <title>IX-01 Capsule After Food</title>
            <description>Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Time Curve From Time 0 to Infinity, Following a Single Dose of IX-01</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20465" spread="38.9"/>
                    <measurement group_id="O2" value="20522" spread="31.7"/>
                    <measurement group_id="O3" value="31613" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Concentration (Cmax) of IX-01</title>
        <time_frame>Pre-dose and up to 96 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IX-01 Aqueous Dispersion While Fasting</title>
            <description>Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O2">
            <title>IX-01 Capsule While Fasting</title>
            <description>Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O3">
            <title>IX-01 Capsule After Food</title>
            <description>Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of IX-01</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1147" spread="39.9"/>
                    <measurement group_id="O2" value="1428" spread="47.9"/>
                    <measurement group_id="O3" value="2518.5" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Peak Plasma Concentration (Tmax) of IX-01</title>
        <time_frame>Pre-dose up to 96 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IX-01 Aqueous Dispersion While Fasting</title>
            <description>Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O2">
            <title>IX-01 Capsule While Fasting</title>
            <description>Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O3">
            <title>IX-01 Capsule After Food</title>
            <description>Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Plasma Concentration (Tmax) of IX-01</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.5" upper_limit="8"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.75" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elimination Half Life (t1/2) of IX-01</title>
        <time_frame>Pre-dose up to 96 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IX-01 Aqueous Dispersion While Fasting</title>
            <description>Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O2">
            <title>IX-01 Capsule While Fasting</title>
            <description>Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O3">
            <title>IX-01 Capsule After Food</title>
            <description>Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half Life (t1/2) of IX-01</title>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="60.7"/>
                    <measurement group_id="O2" value="12.6" spread="32"/>
                    <measurement group_id="O3" value="12.2" spread="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elimination Rate Constant (Kel) of IX-01</title>
        <time_frame>Pre-dose up to 96 hours post last dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IX-01 Aqueous Dispersion While Fasting</title>
            <description>Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O2">
            <title>IX-01 Capsule While Fasting</title>
            <description>Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O3">
            <title>IX-01 Capsule After Food</title>
            <description>Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constant (Kel) of IX-01</title>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046" spread="60.7"/>
                    <measurement group_id="O2" value="0.055" spread="32"/>
                    <measurement group_id="O3" value="0.057" spread="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Measurable Sample of IX-01</title>
        <time_frame>Pre-dose to the time of the last measurable sample</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IX-01 Aqueous Dispersion While Fasting</title>
            <description>Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O2">
            <title>IX-01 Capsule While Fasting</title>
            <description>Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O3">
            <title>IX-01 Capsule After Food</title>
            <description>Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Measurable Sample of IX-01</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19529" spread="34.5"/>
                    <measurement group_id="O2" value="20218" spread="31.1"/>
                    <measurement group_id="O3" value="31270" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of IX-01 in Cerebrospinal Fluid (CSF) After a Single Dose of the Liquid Formulation of IX-01</title>
        <description>Listed by time point of 1, 2, 4, 6 hours post dose</description>
        <time_frame>1, 2, 4 and 6 hours after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IX-01 Aqueous Dispersion While Fasting</title>
            <description>Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of IX-01 in Cerebrospinal Fluid (CSF) After a Single Dose of the Liquid Formulation of IX-01</title>
          <description>Listed by time point of 1, 2, 4, 6 hours post dose</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 1 hour, 1 participant analyzed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 hours, 2 participants analyzed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4 hours, 3 participants analyzed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" spread="17.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 hours, 4 participants analyzed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" spread="21.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs</title>
        <time_frame>Baseline to study completion (approximately 6 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IX-01 Aqueous Dispersion While Fasting</title>
            <description>Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O2">
            <title>IX-01 Capsule While Fasting</title>
            <description>Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
          <group group_id="O3">
            <title>IX-01 Capsule After Food</title>
            <description>Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods&#xD;
IX-01</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 weeks</time_frame>
      <desc>The onset date/time of one non-serious event (toothache) was not recorded, so the treatment arm was unknown and not shown below, otherwise all events that occurred during the study period are shown including those that were unrelated</desc>
      <group_list>
        <group group_id="E1">
          <title>IX-01 Aqueous Dispersion While Fasting</title>
          <description>Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods&#xD;
IX-01</description>
        </group>
        <group group_id="E2">
          <title>IX-01 Capsule While Fasting</title>
          <description>Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods&#xD;
IX-01</description>
        </group>
        <group group_id="E3">
          <title>IX-01 Capsule After Food</title>
          <description>Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods&#xD;
IX-01</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor may choose to collaborate on authorship, and sponsor's agent has 60-day review</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Ixchelsis Limited</organization>
      <phone>44(0)1227-832760</phone>
      <email>ian.osterloh@ixchelsis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

